ArticleCancer reports (Hoboken, N.J.)2026
Observation on the Efficacy of Hyperbaric Oxygen as Adjuvant Therapy for Breast Cancer-Related Wounds: A Case Report.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperbaric oxygen therapy (HBOT) is widely used as a therapeutic intervention for various types of wounds. Studies have shown that in addition to improving local oxygen supply to the wound site, HBOT can also influence cytokine activity, promote the survival of tissue mesh, and thereby facilitate wound healing. Moreover, HBOT inhibits the growth and reproduction of various pathogenic bacteria and enhances the phagocytic capacity of leukocytes, effectively preventing and controlling infection. CASE: This case study involves a 61-year-old female diagnosed with invasive micropapillary carcinoma, who underwent a combination of treatments including radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Nine years post-surgery, the patient experienced a recurrence of left breast cancer, accompanied by cancer wounds with exudate, edema, and ulceration in multiple areas such as the chest and back. Following comprehensive treatment consisting of anti-infective therapy, nutritional support, and edema management, along with three courses of adjuvant HBOT, the patient showed significant improvement in wound exudate and odor, resolution of lymphedema, and a reduction in wound volume, although the wound area did not show notable change.
conclusionThis study implemented a comprehensive care plan for patients with malignant wounds, including measures such as wound debridement, anti-infection treatment, nutritional support, and HBOT. Following the integrated intervention, symptoms including wound exudate, odor, and lymphedema were alleviated, and wound volume was reduced, although no significant change was observed in wound area. The primary benefit of HBOT in malignant wound management lies in symptom control, while its effect on structural wound healing appears limited. Its specific role within multidisciplinary comprehensive care requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.